(Q36882462)

16 August 2017

1 reference

title

Pharmacometrics and the transition to model-based development (English)

1 reference

16 August 2017

Grasela TH

1

1 reference

16 August 2017

Dement CW

2

1 reference

16 August 2017

Kolterman OG

3

1 reference

16 August 2017

Fineman MS

4

1 reference

16 August 2017

Grasela DM

5

1 reference

16 August 2017

Honig P

6

1 reference

16 August 2017

Antal EJ

7

1 reference

16 August 2017

Bjornsson TD

8

1 reference

16 August 2017

Loh E

9

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 August 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

1 reference

16 August 2017

82

1 reference

16 August 2017

2

1 reference

16 August 2017

137-142

1 reference

Paving the critical path: how can clinical pharmacology help achieve the vision?

16 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Learning versus confirming in clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Pharmacokinetic/pharmacodynamic modeling in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Challenges in the transition to model-based development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

Informatics: the fuel for pharmacometric analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

The prospects for "personalized medicine" in drug development and drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

7 January 2021

Gatifloxacin and the elderly: pharmacokinetic-pharmacodynamic rationale for a potential age-related dose reduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

7 January 2021

An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

7 January 2021

Drug safety reform at the FDA--pendulum swing or systematic improvement?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100270

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100270

1 reference

16 August 2017

1 reference